Hemogenyx Pharmaceuticals (LON:HEMO) Sets New 12-Month Low – Time to Sell?

Hemogenyx Pharmaceuticals Plc (LON:HEMO)’s share price reached a new 52-week low during trading on Tuesday . The stock traded as low as GBX 270 ($3.39) and last traded at GBX 284 ($3.57), with a volume of 63610 shares. The stock had previously closed at GBX 378 ($4.75).

Hemogenyx Pharmaceuticals Stock Up 3.1 %

The firm has a market cap of £4.42 billion, a P/E ratio of -33,000.00 and a beta of 3.14. The firm’s 50-day moving average price is GBX 24.12 and its 200 day moving average price is GBX 9.38. The company has a quick ratio of 6.72, a current ratio of 4.38 and a debt-to-equity ratio of 92.09.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.